Home / Health / Clade I Mpox Detected in NYC Traveler, Risk Low
Clade I Mpox Detected in NYC Traveler, Risk Low
17 Mar
Summary
- Severe clade I mpox diagnosed in NYC resident after travel.
- NYC Health emphasizes low public risk and recommends vaccination.
- Clade I mpox historically has higher fatality rate than clade II.
A New York City resident has been diagnosed with clade I mpox, a severe strain of the virus, after recently traveling to Europe. Health officials have confirmed this as the twelfth known case of clade I mpox in the United States. The individual is symptomatic, receiving appropriate medical care, and has been isolating until fully recovered.
Despite the severity of clade I mpox, health officials stressed that the risk to the public in New York City is currently low, with no known local transmission. They strongly recommend that New Yorkers at risk for mpox receive the complete two-dose JYNNEOS vaccine series to prevent infection and minimize symptoms.
Historically, clade I mpox has demonstrated a significantly higher case-fatality rate compared to clade II. However, the U.S. Centers for Disease Control and Prevention notes that supportive medical care can effectively reduce the risk of death for individuals infected with either strain. Initial mpox symptoms often mimic the flu, including fever and swollen lymph nodes, progressing to lesions in specific areas.
